CYP1A1 m1 and m2 polymorphisms: Genetic susceptibility to lung cancer

Revista Portuguesa de Pneumologia

Volumn 16, Issue 1, 2010, Pages 89-98

  Mota, Paula ^a   Moura, David Silva ^b   Vale, Maria Graça ^c   Coimbra, Henriqueta ^a   Carvalho, Lina ^d   Regateiro, Fernando ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Departamento de Zoologia   (Portugal)

^c ISISE Institute for Sustainability and Innovation in Structural Engineering   (Portugal)

^d Instituto de Anatomia Patológica   (Portugal)

Author keywords

CYP1A1; Cytochrome P450; Linkage disequilibrium; Lung cancer; Smoking

Indexed keywords

CARCINOGEN; CYTOCHROME P450 1A1; MUTAGENIC AGENT;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME ACTIVITY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TOBACCO; FEMALE; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MALE; MIDDLE AGED;

CYTOCHROME P-450 CYP1A1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 77951225832     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/s2173-5115(10)70020-8     Document Type: Article

References (39)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266:1821-1828.
2. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995; 14:3-15.
3. Kinzler KW, Vagelstein B. Gatekeepers and caretakers. Nature 1997; 386:761-763.
4. Mukhopadhyay T, Maxwell SA, Roth JA. P53 suppressor gene. Austin (TX): R. G. Landes Co, 1995.
5. Stewart BW, Kleihues P. World cancer report. Lyon: IARC Press, 2003; 182.
6. Ng DPK, Tan KW, Zhao B, et al. CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: influence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation. Cancer Causes and Control 2005; 16:399-405.
7. Lee KM, Kang Daehee, Clapper ML et al. CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among asian populations. Cancer Epidemiol Biomarkers Prev 2008; 17(5):100-125.
8. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet 2007; 32:425.431.
9. Parente B, Queiroga H, Teixeira E, et al. Epidemiological study of lung cancer in Portugal (2000/2002). Rev Port Pneumol 2007; 13(2):255-265.
10. Takano H, Yanagisawa R, Ichinose T, et al. Lung expression of cytochrome P450 1A1 as a possible biomarker of exposure to diesel exhaust particles. Arch Toxicol, 2002; 76:146-151.
11. McClellan RO. Health effects of exposure to diesel exhaust particles. Ann Rev Pharmacol Toxicol 1987; 27:279-300.
12. Hirnoven A. Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer. Environ Health Perspect 1999; 107:37-47.
13. Belogubova EV, Ulibina YM, Suvorova IK, et al. Combined CYP1A1/GSTM1 at-risk genotypes are overrepresented in squamous cell lung carcinoma patients but underrepresented in elderly tumor-free subjects. J Cancer Res Clin Oncol 2006; 132:327-331.
14. Gonzalez FJ, Nebert DW. Evolution of the P450 superfamily: animal plant "warfare", molecular drive and human genetic differences in drug oxidation. Trends in Genetics 1990; 6:182-186.
15. Kawajiri K. CYP1A1. IARC Sci Publ 1999; 148:159-72.
16. Smith G, Stubbins MJ, Harries LW, et al. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 1999; 28 (12):1129-1165.
17. Korytina GF, Akhmadishina LZ, Kochetova OV, et al. Association of polymorphisms of the CYP1A1 and CYP1A2 cytochrome P450 genes with chronic obstructive pulmonary disease in Bashkortostan. Molecular Biology 2008; (42)1:27-36.
18. Spink DC, Spink BC, Cao JQ, et al. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 1998; 19:291-298.
19. Lyakhovich VV, Vavilin VA, Zenkov NK. Menshchikova EB. Activated oxygen metabolites in monooxygenase reactions. Bull Sib Otd Ross Akad Med Nauk 2005; 118:7-12.
20. Kawajiri K, Nakachi K, Imai K, et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990; 263:131-133.
21. Hildebrand CE, Gonzalez FJ, McBride OW, et al. Assignment of the human 2,3,7,8-tetrachlorodibenzo-p dioxininducible cytochrome P1-450 gene to chromosome 15. Nucleic Acids Res 1985; 13: 2009-2016.
22. Song BJ. Friedman FK. Park SS, et al. Monoclonal anti body-directed radioimmunoassay detects cytochrome P-450 in human placenta and lymphocytes. Science 1985; 228: 490-492.
23. Crofts F, Cosma GN, Currie D, et al. A novel CYP1A1 gene polymorphism in African - Americans. Carcinogenesis 1993; 14:1729-1731.
24. Masson LF, Sharp L, Cotton SC, et al. Cytochrome P-450 1A1 Gene Polymorphisms and risk of breast cancer: A HuGE review. American Jornal of Epidemiology 2005; 161(10):245-263.
25. Landi MT, Bertazzi PA, Shields PG, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in Humans. Pharmacogenetics 1994; 4:242-246.
26. McGrath M, Hankinson SE. Cytochrome P450 1A1, cigarette smoking, and risk of endometrial cancer. Cancer Causes Control 2007; 18:1123-1130.
27. Le Marchand L, Guo C, Benhamou S, et al. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer. Cancer Causes and Control 2003; 14:339-346.
28. Nerurkar PV, Okinaka L, Aoki C, et al. CYP1A1, and GSTP1 genetic polymorphisms and urinary 1-hydroxypyrene excretion in non-occupationally exposed individuals. Cancer Epidemiol Biomarkers Prev 2000; 9:1119-1122.
29. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10:1239-1248.
30. Drakoulis N, Cascorbi I, Brokmoller J, et al. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Investig 1994; 72:240-248.
31. Garcia-Closas M, Kelsey KT, Wiencke JK, et al. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility. Cancer Cases and Control 1997; 8:544-553.
32. Shields PG, Caporoso NE, Falk RT, et al. Lung cancer, race and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomark Prev 1993; 2:481-485.
33. Sugimura H, Hamada GS, Suzuki I, et al. CYP1A1 and CYP2E1 polymorphisms and lung cancer, case-control study in Rio de Janeiro, Brazil. Pharmacogenetics 1995; 5:S145-S148.
34. Hayashi SI, Watanable J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphism with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J Biochem 1991; 110:407-411.
35. Nakachi K, Hayashi S, Kawajiri K, Imai K. Association of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation. Carcinogenesis 1995; 16:2209-2213.
36. Le Marchand L, Sivaraman L, Pierce L, et al. Associations of CYP1A1, GSTM1, CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Researcher 1998; 58:4858-4863.
37. Nakachi K, Imai K, Hayashi S, et al. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991; 51:5177-5180.
38. Peter I, Bakker P, Maller J, Yelensky, et al. Evaluating and improving power in whole-gene association studies using fixed marker sets. Nature Genetics 2006: 38(6):663-667.
39. Kato M, Sekine A, Ohnishi Y, et al. Linkage disequilibrium of evolutionary conserved regions in the human genome. Bio Med Central Genomics 2006; 7:326-331.